{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:04:50Z","timestamp":1779894290918,"version":"3.53.1"},"reference-count":0,"publisher":"Laeknabladid\/The Icelandic Medical Journal","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["lbl"],"published-print":{"date-parts":[[2026,5,5]]},"abstract":"<jats:p>Huntington\u2019s disease (HD) is a rare, autosomal dominant neurodegenerative disorder characterized by progressive movement disturbances, psychiatric symptoms, and cognitive impairment. The disease is caused by an increased number of repeats of the cytosine\u2013adenine\u2013guanine (CAG) base sequence in the HTT gene, leading to the production of a huntingtin protein with toxic gain-of-function properties and the accumulation of protein aggregates in neurons, resulting in neurodegeneration. The prevalence of HD has previously been reported to be low in Iceland compared with other European countries. However, recent studies indicate an increased prevalence, likely due to improved diagnostic capabilities and greater use of genetic testing. Diagnosis is based on clinical evaluation, family history, and confirmation by genetic testing. Currently, no disease-modifying treatment is available, but symptomatic management and a multidisciplinary approach can improve patients\u2019 functional abilities and quality of life. This review article discusses the epidemiology, genetics, clinical manifestations, diagnosis, and treatment of Huntington\u2019s disease, with particular emphasis on recent Icelandic research findings and future prospects.<\/jats:p>","DOI":"10.17992\/lbl.2026.05.891","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:31:37Z","timestamp":1779892297000},"page":"216-222","source":"Crossref","is-referenced-by-count":0,"title":["Huntington\u00b4s disease \u2013 overview"],"prefix":"10.17992","volume":"112","author":[{"given":"Saga","family":"Briem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsteinn","family":"Bjornsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vigdis","family":"Stefansdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon J","family":"Jonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olafur A","family":"Sveinsson","sequence":"additional","affiliation":[{"name":"University of Iceland, Faculty of Medicine, Department of Neurology, Sahlgrenska University hospital, Gothenburg, Sweden, Department of Genetics and Molecular Medicine, Landspitali University Hospital, Reykjav\u00edk, Iceland, Department of Neurology, University Hospital of Iceland, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7439","published-online":{"date-parts":[[2026,5,5]]},"container-title":["Laeknabladid"],"original-title":["Huntington-sj\u00fakd\u00f3mur \u2013 Yfirlitsgrein"],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:31:38Z","timestamp":1779892298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.laeknabladid.is\/tolublod\/2026\/05\/yfirlitsgrein.-huntington-sjukdomur"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":0,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2026,5,5]]},"published-print":{"date-parts":[[2026,5,5]]}},"URL":"https:\/\/doi.org\/10.17992\/lbl.2026.05.891","relation":{},"ISSN":["0023-7213","1670-4959"],"issn-type":[{"value":"0023-7213","type":"print"},{"value":"1670-4959","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]}}}